1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries. CA. Cancer J Clin. 2021;71: 209–249.
2. Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the
turn of the third millennium. Front Pharmacol. 2018; 9.
3. Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current
Challenges in Cancer Treatment. ClinTher. 2016; 38: 1551–1566.
4. El-Awady R, Saleh E, Hashim A, Soliman N, Dallah A, Elrasheed A, Elakraa G.The role
of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy. Front
Pharmacol. 2017; 7: 1–15.
5. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different
mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull. 2017; 7: 339–348.
6. Chabner BA, Longo DL. Cancer chemotherapy, immunotherapy and biotherapy: Principles
and practice, sixth edition, Cancer Chemotherapy, Immunotherapy and Biotherapy:
Principles and Practice. 2018; Sixth Edition.
7. Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the
effects of current chemotherapy drugs and natural agents in treating non-small cell lung
cancer. Biomed. 2017; 7: 12–23.
8. Huang XM, Yang, Z.J, Xie QZ, Zhang ZK, Zhang,HM, Ma JY. Natural products for
treating colorectal cancer: A mechanistic review. Biomed. Pharmacother. 2019;117:
109142.
9. Rejhová A, Opattová A, Čumová A, Slíva D, Vodička P. Natural compounds and
combination therapy in colorectal cancer treatment. Eur J Med Chem. 2018;144:582-594.
10. Mancini R, Modlin J, 2011. Sequence : A Review of the Literature and Creation of a
Sequencing Chart. J Hematol Oncol Pharm. 2011;1: 17–25.
11. Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, et al. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. Breast 2017;33: 104–108.
12. Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398.
13. Vennepureddy A, Atallah JP, Terjanian T. Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature. World J Oncol. 2015; 6: 429–436.
14. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci USA. 2001; 98: 12009.
15. Kawale AS, Povirk LF. Tyrosyl-DNA phosphodiesterases: Rescuing the genome from the risks of relaxation. Nucleic Acids Res. 2018; 46: 520–537.
16. Pommier Y, Huang S, Yin N, Gao R, Das BB, Murai J, Marchand C. Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst). 2014; 19:114.
17. Dean RA, Fam HK, An J, Choi K, Shimizu Y, Jones SJM, Boerkoel CF, Interthal H,
Pfeifer TA. Identification of a putative tdp1 inhibitor (CD00509) by in vitro and cell-
based assays. J Biomol Screen.2014; 19; 1372–1382.
18. Miao ZH, Agama K, Sordet O, Povirk L, Kohn KW, Pommier Y. Hereditary ataxia
SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I
cleavage complexes. DNA Repair (Amst). 2006; 5:1489–1494.
19. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase i inhibition in colorectal
cancer: Biomarkers and therapeutic targets. Br J Cancer 2012;106:18–24.
20. Liu C, Zhou S, Begum S, Sidransky D, Westra WH, Brock M, Califano JA. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer. 2007; 55: 303–311.
21. Leone S, Recinella L, Chiavaroli A, Orlando G, Ferrante C, Leporini L, Brunetti L, Menghini L. Phytotherapic use of the Crocus sativus L. (Saffron) and its potential applications: A brief overview. Phyther Res.2018; 32: 2364–2375.
22. Rezaee R, Hosseinzadeh H. Safranal: From an aromatic natural product to a rewarding pharmacological agent. Iran J Basic Med Sci. 2013;16:12–26.
23. Milajerdi A, Djafarian K, Hosseini B. The toxicity of saffron (Crocus sativus L.) and its constituents against normal and cancer cells. J. Nutr. Intermed. Metab. 2016; 3: 23-32.
24. Riahi-Zanjani B, Balali-Mood,M, Mohammadi E, Badie-Bostan H, Memar B, Karimi G. Safranal as a safe compound to mice immune system. Avicenna J phytomedicine 2015; 5: 441–9.
25. Zhang SP, Huang JN, Jin N, Wang XL, Jin CC. Safranal inhibits the migration and
invasion of human oral squamous cell carcinoma cells by overcoming epithelial-
mesenchymal transition. Biomed. Res.2017; 28: 817–821.
26. Al-Hrout A, Chaiboonchoe A, Khraiwesh B, Murali C, Baig B, El-Awady R, Tarazi H, Alzahmi A, Nelson DR, GreishYE, Ramadan,W, Salehi-Ashtiani K, Amin A. Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells. Sci Rep. 2018; 8: 16951.
27. El-Awady RA, Saleh EM, Dahm-Daphi J. Targeting DNA double-strand break repair: Is it the right way for sensitizing cells to 5-fluorouracil? Anticancer. Drugs. 2010; 21: 277–287.
28. Berenbaum MC. What is synergy? Pharmacol Rev.1989; 41: 93 LP – 141.
29. Ramadan WS, Talaat IM, Hachim MY, Lischka A, Gemoll T, El-Awady R. The impact of CBP expression in estrogen receptor-positive breast cancer. Clin Epigenetics. 2021; 13:1–18.
30. Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AHA.. Altered Expression of
Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired
Doxorubicin Resistance in Breast Cancer Cells. Cell Biochem Biophys. 2009;55(2):95-
105.
31. Meisenberg C, Ward SE, Schmid P, El-Khamisy SF. TDP1/TOP1 ratio as a promising indicator for the response of small cell lung cancer to topotecan. J Cancer Sci Ther. 2014; 6: 258–267.
32. El-Awady RA, Saleh EM, Ezz M, Elsayed AM. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicol Appl Pharmacol. 2011; 255: 271–286.
33. Pommier Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006; 6: 789–802.
34. El-Awady RA, Ali MM, Saleh EM, Ghaleb FM. Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition. Saudi Med J. 2008; 29: 558–564.